[Two cases of hemodialysis patients with absolute hypoparathyroidism or normal parathyroid function who were suffering from prostate carcinoma].
In recent years, the incidence of prostate carcinoma in patients with renal failure is increasing. But it is difficult to diagnose the occurrence of this neoplasm because of decrease of urinary volume in these patients. Two hemodialysis patients (age: 64, 68 years, the duration of hemodialysis: 10, 8 years) suffering from prostate carcinoma were treated with androgen deprivation therapy, which accelerates bone resorption. (This kind of osteoporosis is often treated by bisphosphonate, but this treatment is prohibited in hemodialysis patients.) Both serum testosterone and estradiol went down to the extremely lower levels in these patients. Thereafter, one (case 2) of them was maintained under absolute hypoparathyroidism by the conservative therapy with vitamin D. As a result, bone mineral density of the patient (case 2) was well maintained during one year. In conclusion, hypoparathyroidism was helpful to prevent bone loss in patients receiving androgen deprivation therapy.
Yajima
Aiji
A
Towa Hospital, Department of Urology.
Ogawa
Yoshihide
Y
Tominaga
Takashi
T
Inou
Tsunamasa
T
Otsubo
Osamu
O
Yagi
Shigeru
S
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001862:Bone Resorption / Q000139:chemically induced; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000517:prevention & control*; D010281:Parathyroid Hormone / Q000097:blood*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D006435:Renal Dialysis; D014807:Vitamin D / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D010281:Parathyroid Hormone; D014807:Vitamin D; D007987:Gonadotropin-Releasing Hormone